Clarifying the Vascular Aspects of Dementia

Clarifying the Vascular Aspects of Dementia - Vascular aspects in dementia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55875

Enrollment

280

Registered

2019-08-20

Start date

2019-10-11

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hersenaandoening Alzheimer's disease dementia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who attended the memory clinic of the Leiden University Medical Center/ Bronovo/ Reinier de Graaf hospital within one year ago • Diagnosed with probable Alzheimer's disease • Diagnosed as Mild cognitive impairment • Diagnosed as Subjective cognitive impairment • Diagnosed as Vascular dementia • Capable of giving informed consent (see appendix)Control subjects • Healthy adults without memory complaints aged between 40-90 years old t>üâ

Exclusion criteria

Exclusion criteria: - Contra-indication to MRI scanning: • Claustrophobia • Pacemakers and defibrillators • Nerve stimulators • Intracranial clips • Intraorbital or intraocular metallic fragments • Cochlear implants • Ferromagnetic implants • Hydrocephaluspump • Intra-utrine device (not all types) • An iron wire behind the teeth • Permanent make-up • Tattoos above the shoulders (not all)- Specific contraindications to fMRI • Seizure within prior year. • Noncorrectable visual impairment.- MMSE

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints: 1) 3T MRI: the amplitude of the BOLD response in percentage signal change between stimulus on and off, time-to-peak response (sec), and time-to-baseline (sec) after discontinuation of the visual stimulus, classic signs of CAA (intracranial hemorrhage, lobar microbleeds, subarachnoidal hemorrhage and superficial siderosis) and SVD markers (number of small subcortical infarcts and lacunes, volume of white matter hyperintensities (WMHs), perivascular spaces in the basal ganglia and centrum semiovale, number and location of microbleeds and grey matter volume). 2) Neuropsychological assessment 3) Baseline characteristics, 4) DNA: APOE * genotype.	—

Measure

Time frame

Main study parameters/endpoints: 1) 3T MRI: the amplitude of the BOLD response in percentage signal change between stimulus on and off, time-to-peak response (sec), and time-to-baseline (sec) after discontinuation of the visual stimulus, classic signs of CAA (intracranial hemorrhage, lobar microbleeds, subarachnoidal hemorrhage and superficial siderosis) and SVD markers (number of small subcortical infarcts and lacunes, volume of white matter hyperintensities (WMHs), perivascular spaces in the basal ganglia and centrum semiovale, number and location of microbleeds and grey matter volume). 2) Neuropsychological assessment 3) Baseline characteristics, 4) DNA: APOE * genotype.

—

Countries

Netherlands

Outcome results